Definitive Contract HHSD200201794414C
Award Date
7/1/17
Potential Completion Date
6/30/18
Potential Value
$85M
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Whitehouse Station, Readington Township, NJ, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $102,189,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines. The contract is a definitive, firm fixed-price contract without any set-aside designation. Glaxosmithkline has provided a range of pharmaceutical goods and services to various U.S. government agencies, including vaccines, antiviral medications, and COVID-19 treatments. The company also...
This is a definitive contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, doing business as Glaxosmithkline. The $12,136,000.00 firm fixed price contract is for the delivery of adult influenza (flu) vaccines. The contract has no set-aside designation and the place of performance is in Atlanta, Georgia. Glaxosmithkline is a pharmaceutical company that provides various vaccines, antiviral medications, and other...
This is a definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC on December 23, 2016 for the 2017 adult flu season. The firm fixed price contract has a ceiling value of $12,408,000.00 and a performance period ending February 28, 2018. The contract does not have a set-aside designation. GlaxoSmithKline, a pharmaceutical company, has provided a range of products to U.S. government agencies through federal contracts, including influenza...
This federal contract award was made by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC, a pharmaceutical company that provides vaccines, antiviral medications, and other pharmaceutical products to U.S. government agencies. The contract has a total ceiling value of $213,831.06 and was awarded on a firm fixed price basis with no set-aside designation. It is a delivery order under GlaxoSmithKline's existing General Services Administration Federal Supply Schedule...
This is a federal contract award to GlaxoSmithKline, LLC, a pharmaceutical company, by the Centers for Disease Control and Prevention (CDC) for the provision of influenza vaccines. The contract, valued at $9,888,000.00, is a definitive contract with a firm fixed price. The award was made on December 18, 2015, and the ultimate completion date is February 28, 2017. The contract has no set-aside designation, and the place of performance is in Research Triangle Park, North Carolina....
This is a modification to a $49,999,745.68 firm fixed price delivery order contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Glaxosmithkline, LLC. The contract is for the provision of pharmaceutical products including vaccines, antiviral medications, and vaccine adjuvants to support various U.S. government agencies. The contract has no set-aside designation. Glaxosmithkline has a history of providing a range of pharmaceutical products...
This is a $50,556,695.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company that provides vaccines, antiviral medications, and other pharmaceutical products to U.S. government agencies. The contract, titled "2016 VFA - GSK", is for a firm fixed price and has an ultimate completion date of June 30, 2017. It is not a set-aside contract. Glaxosmithkline has provided a range of pharmaceutical goods and...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed price delivery order contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure $40,551,654.40 in products. The contract has no set-aside designation. Glaxosmithkline provides various pharmaceutical goods and services to multiple federal agencies, including vaccines, antiviral medications, and drug development support. This award was likely made under one of Glaxosmithkline's...
This is a federal contract award by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC, a pharmaceutical company, for the delivery of influenza vaccines. The contract is a Delivery Order issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with a Firm Fixed Price pricing type and a potential value of $1,319,230.00. There was no set-aside designation used for this award. GlaxoSmithKline has provided a...
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) to Glaxosmithkline, LLC, doing business as Glaxosmithkline, for the provision of vaccines. The contract has a potential value of $149,437.89 and was issued under the General Services Administration (GSA) Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs. The contract supports disease prevention efforts, immunization programs, and drug stockpiling initiatives....